PeerView (PVI) is a leading provider of high-quality, innovative continuing education (CME/CE/CPE and MOC) for clinicians and their interprofessional teams. Combining evidence-based medicine and instructional expertise, PeerView activities improve the knowledge, skills, and strategies that support clinical performance and patient outcomes. PeerView makes its educational programming and expert-led presentations and symposia available through its network of popular podcast channels to support specific specialties and conditions. Each episode includes a link to request CME/CE credit for participation. PeerView is solely responsible for the selection of topics, the preparation of editorial content, and the distribution of all materials it publishes.
http://ww2.peerview.com
Matthew I. Milowsky, MD, FASCO - Fresh Perspectives on Moving Toward Personalized Care for Bladder Cancer: Tips, Tools, and Strategies for Leveraging the Latest Advancements Across the Disease Spectrum
Go online to PeerView.com/KPE860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Management of advanced/metastatic urothelial cancer has undergone a significant transformation with the addition of PD-1– and PD-L1–targeting immune checkpoint inhibitors (ICIs) to the treatment armamentarium. These advances are quickly moving into early-stage disease, including emerging bladder-sparing and perioperative approaches, which has recently led to the first regulatory approval of an ICI as adjuvant therapy in high-risk muscle-invasive bladder cancer (MIBC). In this activity, based on a recent live symposium, experts use real-world cases and mini lectures to illustrate practical tips and treatment selection strategies for patients with MIBC or NMIBC (non–muscle-invasive bladder cancer), including clinical trial opportunities, bladder-preservation options, and perioperative regimens. This activity also examines approaches for personalized care in metastatic urothelial cancer (mUC), both in the frontline setting and in progressive disease. Upon completion of this activity, participants should be better able to: Assess new evidence on therapeutic strategies for bladder cancer management across the disease continuum based on innovative drug delivery approaches, modern immunotherapy regimens, and novel targeted agents; Implement novel and emerging therapeutic approaches into personalized treatment plans for patients with varying stages of bladder cancer considering the available evidence, current guidelines, and principles of multidisciplinary and patient-centered care; and Integrate evidence- and team-based management protocols to address the unique suite of adverse events associated with novel therapeutics for bladder cancer